OG0-093専門知識訓練、OG0-093資格試験

さらに、JPTestKing OG0-093ダンプの一部が現在無料で提供されています：https://drive.google.com/open?id=1j7Jcjx6anMqot0w_9edlWnUECDgOGmYB

弊社のOG0-093問題集は大勢の専門家たちの努力で開発される成果です。初心者といい、数年IT仕事を従事した人といい、我々JPTestKingのThe Open Group　OG0-093問題集は最良の選択であると考えられます。なぜならば、弊社は高品質かつ改革によってすぐに更新できるOG0-093問題集を提供できるからです。

Open Group OG0-093認定試験は、TOGAFフレームワークを十分に理解する必要がある包括的な試験です。この試験では、エンタープライズアーキテクチャ、アーキテクチャ開発方法、アーキテクチャコンテンツフレームワーク、アーキテクチャガバナンスなど、幅広いトピックをカバーしています。この試験では、TOGAFフレームワークを実際のシナリオに適用する候補者の能力もテストします。

>> OG0-093専門知識訓練 <<

OG0-093資格試験 & OG0-093英語版

JPTestKingは、魅力的なキャラクターで世界中の試験受験者を招きます。当社の専門家は彼らの卓越性に大きく貢献しました。したがって、試験をシミュレートするOG0-093が最良であると率直に言うことができます。 OG0-093学習教材のコンテンツを作成する取り組みは、学習ガイドの開発につながり、完成度を高めます。そのため、模擬試験は間違いなくレビューの耐久性を高めています。関心を集め、いくつかの難しい点を簡素化するために、当社の専門家は、OG0-093試験の合格に役立つように、OG0-093学習教材の設計に最善を尽くしています。

The Open Group OG0-093：TOGAF 9 Combined Part 1およびPart 2試験は、企業アーキテクチャの分野における候補者の熟練度を評価する包括的な評価です。この認定試験は、TOGAF 9の原則、概念、およびアーキテクチャフレームワークに対する個人の知識と理解をテストするように設計されています。

Open Group OG0-093試験は、企業アーキテクチャに強い理解を持ち、TOGAF 9フレームワークでの作業経験がある専門家を対象としています。この試験を受ける前に、候補者が少なくとも2年間のITアーキテクチャの経験を持っていることが推奨されています。試験は2つのパートに分かれ、パート1は基礎的なコンセプトを、パート2は高度なトピックを扱います。

The Open Group TOGAF 9 Combined Part 1 and Part 2 認定 OG0-093 試験問題 (Q406-Q411):

質問 # 406
Which one of the following statements about TOGAF Building Blocks is true?

A. Building blocks at a functional level are known as Solutions Building Blocks
B. The gap analysis technique should be used to identify building blocks for re-use
C. Solutions Building Blocks are selected in Phases A, B, C and D
D. The specification of a building block should be loosely coupled to its implementation

正解：D

質問 # 407
Which of the following is an objective of Phase B, Business Architecture?

A. To demonstrate how stakeholder concerns are addressed in the Business Architecture
B. To finalize the Architecture Vision and Architecture Definition documents
C. To maximize the business value from the architecture
D. To confirm the ability of the enterprise to undergo change
E. To develop a Target Technology Architecture to support the business

正解：A

質問 # 408
Which of the following is NOT an objective for Phase B, Business Architecture?

A. Developing the Target Business Architecture
B. Defining the Strategic Business Plan
C. Describing the Baseline Business Architecture
D. Selecting relevant viewpoints for key stakeholders

正解：B

質問 # 409
Within the Architecture Repository, what does the class of information knows as the Architecture Capability include?

A. Patterns, templates, and guidelines used to create new architectures.
B. A record of the governance activity across the enterprise
C. Specifications to which architecture must conform
D. The organization specific architecture framework, including a method for architecture development and a metamodel for architecture content
E. Parameters, structures, and processes to support governance of the repository

正解：E

解説：
Explanation/Reference:
Reference: http://pubs.opengroup.org/architecture/togaf91-doc/arch/chap41.html

質問 # 410
Scenario
Please read this scenario prior to answering the Question
You are serving as the Lead Architect for an enterprise architecture project team within a leading multinational pharmaceutical and medical devices manufacturer. Its brands include numerous household names for medications and first aid supplies.
The company has a long history of innovating new treatments for many common illnesses and diseases. Prior to launching a new treatment, the company has to demonstrate Its effectiveness and safety in a set of clinical trials that satisfy the regulatory requirements of the countries in the target markets. All clinical trials are undertaken by its research laboratories, which employ over 10,000 people at separate facilities in the United Kingdom, United States, Sweden, France, Canada, India, China and Japan. In addition to internal research and development activities the company is also involved in publicly funded collaborative research projects, with other industrial and academic partners.
The Enterprise Architecture group within the company has been engaged in an architecture development project to create a secure networked collaboration system that will allow researchers at its product development laboratories worldwide to share information about their clinical trials. This system will also connect with external partners.
The Enterprise Architecture group within the company has been engaged in an architecture development project to create a secure networked collaboration system that will allow researchers at its product development laboratories worldwide to share information about their clinical trials. This system will also connect with external partners.
The Enterprise Architecture group is a mature organization. They use the TOGAF 9 ADM with extensions required to support current good manufacturing practices and good laboratory practices in their target markets. Due to the highly sensitive nature of the information that is managed, special care was taken to ensure that each architecture domain included an examination of the security and privacy issues that are relevant.
The Executive Vice President for Clinical Research is the sponsor of the Enterprise Architecture activity. She has stated that the changes to the enterprise architecture for the new system will need to be rolled out in stages on a regional basis that minimizes disruptions to ongoing clinical trials.
Refer to the Scenario
You have been asked to recommend the approach to identify the work packages that will be included in the Transition Architecture(s).
Based on TOGAF, which of the following is the best answer?

A. Use a Consolidated Gaps, Solutions and Dependencies Matrix as a planning tool. For each gap classify whether the solution is either a new development, purchased solution, or based on an existing product. Group the similar solutions together to define the work packages. Regroup the work packages into a set of Capability Increments to transition to
the Target Architecture taking into account the schedule for clinical trials.
B. Create an Implementation Factor Assessment and Deduction Matrix and a Consolidated Gaps, Solutions and Dependencies Matrix. For each gap, identify a proposed solution and classify it as new development, purchased solution, or based on an existing product. Group similar solutions together to form work packages. Identify dependencies between work packages factoring in the clinical trial schedules. Regroup the packages into a set of Capability Increments scheduled into a series of Transition Architectures.
C. Determine the set of Solution Building Blocks required by identifying which Solution Building Blocks need to be developed and which need to be procured. Eliminate any duplicate building blocks. Group the remaining Solution Building Blocks together to create the work packages using a CRUD matrix. Rank the work packages in terms of cost and select the most cost-effective options for inclusion in a series of Transition Architectures. Schedule the roll out of the work packages to be sequential across the geographic regions.
D. Group the Solution Building Blocks from a Consolidated Gaps, Solutions and Dependencies Matrix into a set of work packages. Using the matrix as a planning tool, regroup the work packages to account for dependencies. Sequence the work packages into the Capability Increments needed to achieve the Target Architecture. Schedule the rollout one region at a time. Document the progression of the enterprise architecture using a state evolution table.

正解：A

質問 # 411
......

OG0-093資格試験: https://www.jptestking.com/OG0-093-exam.html

ちなみに、JPTestKing OG0-093の一部をクラウドストレージからダウンロードできます：https://drive.google.com/open?id=1j7Jcjx6anMqot0w_9edlWnUECDgOGmYB